Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

DKD: diabetic kidney disease; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HbA1c: glycated haemoglobin; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate (CKD-EPI); ALP: alkaline phosphatase; ALT: alanine aminotransferase; T4: thyroxine; TSH: thyroid stimulating hormone; iPTH: intact parathyroid hormone; 25 (OH)D: 25-hydroxyvitamin D; WCC: white cell count. *Healthy volunteers were excluded sequentially based on a single criterion.Stepwise regression to determine which variables were associated with LN dp-ucMGP among healthy volunteers and participants with DM with and without DKD.VariableHealthy Volunteers (n = 141)Diabetes Mellitus (n = 192)Coefficient95% CIP-ValueCoefficient95% CIP-ValueConstant4.964(4.296, 5.632)<0.0013.11(0.22, 5.99)0.035BMI (kg/m2)0.010(0.000, 0.020)0.0480.017(0.007, 0.026)<0.001SBP (mmHg)−0.004(−0.008, −0.001)0.017DBP (mmHg)0.005(−0.001, 0.011)0.078HbA1c (mmol/mol)−0.012(−0.025, 0.000)0.0590.003(0.000, 0.006)0.081CRP (mg/L)^0.042(−0.001, 0.085)0.0550.076(0.026, 0.125)0.003Sodium (mmol/L)0.027(0.008, 0.047)0.006eGFR (ml/min/1.73 m2)−0.008(−0.011, −0.006)<0.001Phosphate (mmol/L)−0.24(−0.503, 0.023)0.074GGT (U/L)^0.085(0.010, 0.16)0.027Triglycerides (mmol/L)^−0.072(−0.170, 0.025)0.145TSH (mIU/L)0.032(−0.000, 0.064)0.05iPTH (ng/L)^0.12(0.020, 0.219)0.019NT-proBNP (ng/L)^0.057(0.006, 0.108)0.03uACR (mg/mmol)^0.03(−0.007, 0.066)0.111Haemoglobin (g/dL)0.06(0.019, 0.100)0.004−0.055(−0.093, −0.018)0.004Male Gender−0.173(−0.265, −0.082)<0.001−0.101(−0.214, 0.011)0.079All variables detailed in Table 1 (except creatinine) and gender were included in the model.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Multiple reported designs.

Multiple reported designs

More than one design is explicitly reported; examine the supporting methods.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A cross-sectional study was carried out between March 2016 and March 2018 at GUH/NUIG to recruit healthy volunteers (HVs).

Source: Methods.

Participants were recruited by convenience consecutive sampling at routine DM, nephrology and diabetic renal clinics at GUH.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Plasma dephosphorylated-uncarboxylated Matrix Gla-Protein (dp-ucMGP): reference intervals in Caucasian adults and diabetic kidney disease biomarker potential

Multiple reported designs · Scientific Reports · 2019

Original publication title

Plasma dephosphorylated-uncarboxylated Matrix Gla-Protein (dp-ucMGP): reference intervals in Caucasian adults and diabetic kidney disease biomarker potential

Tomás Patrick Griffin; Md Nahidul Islam; Deirdre Wall; John Ferguson; Damian Gerard Griffin; Matthew Dallas Griffin; Paula M. O’Shea

© The Author(s) 2019

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Recent studies suggest a possible association between dephosphorylated-uncarboxylated MGP (dp-ucMGP) and glomerular filtration rate (GFR). This study aimed to establish normative data in an adult Caucasian population and to explore the potential utility of dp-ucMGP in patients with diabetes mellitus (DM) with and without diabetic kidney disease (DKD). Healthy volunteers (HVs) (cross-sectional study) and participants with DM (prospective cohort study) were recruited. Plasma dp-ucMGP was measured using the IDS®-iSYS Ina Ktif (dp-ucMGP) assay. Of the HVs recruited (n = 208), 67(32.2%) were excluded leaving a reference population of 141(67.8%) metabolically healthy participants with normal kidney function.

Plasma dp-ucMGP RIs were <300 to 532 pmol/L. There were 100 eligible participants with DKD and 92 with DM without DKD. For the identification of participants with DKD, the area under the receiver operating characteristic curve (AUC) for dp-ucMGP was 0.842 (95%CI:0.799 to 0.880; p < 0.001). Plasma dp-ucMGP demonstrated similar ability to urine albumin:creatinine ratio (uACR) to detect participants with DM and renal function decline. Among patients with DM, there was a negative correlation between natural log (LN) dp-ucMGP and eGFR (r = −0.7041; p < 0.001) and rate of change in renal function [%change (r = −0.4509; p < 0.001)] and a positive correlation between LN dp-ucMGP and LN uACR (r = 0.3392; p < 0.001).

These results suggest the potential for plasma dp-ucMGP with well-defined RIs to identify adults at high risk for vascular disease in the context of progressive DKD.

Authors’ abstract

Recent studies suggest a possible association between dephosphorylated-uncarboxylated MGP (dp-ucMGP) and glomerular filtration rate (GFR). This study aimed to establish normative data in an adult Caucasian population and to explore the potential utility of dp-ucMGP in patients with diabetes mellitus (DM) with and without diabetic kidney disease (DKD). Healthy volunteers (HVs) (cross-sectional study) and participants with DM (prospective cohort study) were recruited. Plasma dp-ucMGP was measured using the IDS®-iSYS Ina Ktif (dp-ucMGP) assay. Of the HVs recruited (n = 208), 67(32.2%) were excluded leaving a reference population of 141(67.8%) metabolically healthy participants with normal kidney function.

Plasma dp-ucMGP RIs were <300 to 532 pmol/L. There were 100 eligible participants with DKD and 92 with DM without DKD. For the identification of participants with DKD, the area under the receiver operating characteristic curve (AUC) for dp-ucMGP was 0.842 (95%CI:0.799 to 0.880; p < 0.001). Plasma dp-ucMGP demonstrated similar ability to urine albumin:creatinine ratio (uACR) to detect participants with DM and renal function decline. Among patients with DM, there was a negative correlation between natural log (LN) dp-ucMGP and eGFR (r = −0.7041; p < 0.001) and rate of change in renal function [%change (r = −0.4509; p < 0.001)] and a positive correlation between LN dp-ucMGP and LN uACR (r = 0.3392; p < 0.001).

These results suggest the potential for plasma dp-ucMGP with well-defined RIs to identify adults at high risk for vascular disease in the context of progressive DKD.

Publication and source details

Original title: Plasma dephosphorylated-uncarboxylated Matrix Gla-Protein (dp-ucMGP): reference intervals in Caucasian adults and diabetic kidney disease biomarker potential

Tomás Patrick Griffin; Md Nahidul Islam; Deirdre Wall; John Ferguson; Damian Gerard Griffin; Matthew Dallas Griffin; Paula M. O’Shea

Scientific Reports · 2019

© The Author(s) 2019https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/100010661EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)634086Islam Md Nahidul

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T18:12:28.082597+00:00

DOI: 10.1038/s41598-019-54762-2 · PMC6895103